Clostridium Difficile Diagnostics Market to Surpass US$ 1,450.29 Mn by 2030

Global Clostridium Difficile Diagnostics Market, by Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Stool Test (GDH Antigen Test and Toxin A and B Test), Blood Test, Colonoscopy or Sigmoidoscopy and Others), by End User (Hospitals, Diagnostic Centers, Specialty Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 838.05 Million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing awareness campaigns by several government and non-government organizations are expected to play important role in driving the market growth for the forecast period.  For instance, the 'See C. diff' campaign, launched by Peggy Lillis Foundation, a not-for-profit corporation foundation, in December 2020, announced that they have attained their objective by reaching more than 250,000 Americans in order to spread awareness regarding Clostridium Difficile. The organization launched the 'See C. diff' to commemorate C.diff (Clostridium Difficile) awareness campaign in 2019, and reached about 80,000 people.

Moreover, on December 4, 2021, the Peggy Lillis Foundation, announced that they have reached more than 1 million people during C. diff awareness campaign in U. S.

Global Clostridium Difficile Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic. The COVID-19 pandemic had a limited  impact on the clostridium difficile diagnostics market, according to an article published by Elsevier Inc., in August 2022, during the COVID-19 pandemic, several factors, such as improved hand hygiene, social distancing, and restricted hospital referral, may have had an influence on the epidemiology of Clostridioides difficile infections (CDI). From 2020 and the previous five monitoring years, the yearly CDI incidence rate of nine hospitals participating in the Dutch sentinel CI surveillance with complete data was compared. The first Dutch COVID-19 wave, which ran from March 13 to May 12, 2020, and the second wave, which ran from September 17, 2020, to January 1, 2021, were compared to the corresponding time periods in 2015 through 2019. For changes in trends over time, all analyses were corrected. In 2020, the yearly CDI incidence rate was lower than in earlier years. The proportion of CDI patients who had severe CDI increased during the second wave compared to the first (25.8% in 2020 vs. 17.9% in 2015–2019; risk ratio: 1; 95% confidence interval: 1-23). After adjustment for delayed C. difficile diagnostics (≥8 days from start symptoms), the increase disappeared. Delayed C. difficile diagnostics was indeed more common during the second wave (RR 1·7; 95%CI 1·1-2·6), but only for community-onset CDI (CO-CDI).

This study shows that a higher percentage of severe CDI cases was observed during the second COVID-19 wave. This may partially be caused by delayed diagnostics, potentially due to decreased visits to a physician or restricted hospital referral for CO-CDI patients.

Global Clostridium Difficile Diagnostics Market: Key Developments

For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA (supervisory control and data acquisition) is in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.

Browse 25 Market Data Tables and 29 Figures spread through 172 Pages and in-depth TOC on “Global Clostridium Difficile Diagnostics Market”-  Forecast to 2030, Global Clostridium Difficile Diagnostics Market, by Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Stool Test (GDH Antigen Test and Toxin A and B Test), Blood Test, Colonoscopy or Sigmoidoscopy and Others), by End User (Hospitals, Diagnostic Centers, Specialty Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/clostridium-difficile-diagnostics-market-5315

Moreover, increasing prevalence of clostridium difficile is expected to drive the market growth over the forecast period. For instance, according to an article published by the National Center for Biotechnology Information, in August 2020, in Saudi Arabia there was an increasing trend of healthcare-associated CDIs from 17% in 2001 to 20% in 2018 out of all suspected diarrhea samples tested.

Key Takeaways of the Global Clostridium Difficile Diagnostics Market:

• The global clostridium difficile diagnostics market is expected to exhibit a CAGR of 7.1% during the forecast period owing to various advantages of current diagnostic methods such as Nucleic Acid Amplification Tests (NAAT) over conventional immunoassays as well another tests as they have new diagnostic approaches. Toxin enzyme immunoassays (EIA) are insufficiently sensitive and may underdiagnose Clostridium Difficile Infection, which is one reason why enzyme immunoassay has been widely adopted. Advancements in the diagnostic tests such as shortened the time to results is expected to boost the growth of the segment over the forecast period.
• Among diagnostic test, Enzyme Immunoassays segment is estimated to hold a dominant position in the global clostridium difficile diagnostics market over the forecast period, owing to increasing product developments to meet the regulatory guidelines by market players is expected to drive the segment growth over the forecast period. For instance, in February 2018, TECHLAB, Inc., manufactures a variety of in vitro diagnostics for enteric diseases had announced that its products meet the updated Infectious Disease Society of America (IDSA) and Society of Healthcare Epidemiology of America (SHEA) clinical practice guidelines for Clostridium difficile.
• On the basis of end users, hospitals segment is estimated to account for the largest market share in the global clostridium difficile diagnostics market over the forecast period, due to increasing number of hospital acquired infections leading to increasing number clostridium difficile and thereby increase in number of diagnostic test in the hospitals. For instance, according to an article published by the LANCET Regional Health Europe, on June 27, 2022, stated that the proportion of hospitalized clostridium difficile infection, patients with severe clostridium difficile infection increased during the second wave of COVID-19 in 2020 compared to the same time periods the year before.
• Major players operating in the global clostridium difficile diagnostics market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Inc., Abbott Laboratories, Trinity Biotech Plc., Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc